Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ggi.13453 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Direct Evaluation of Salivary Antioxidant Properties in Patients with Down Syndrome for assessment to Periodontal Disease and Premature Aging.
Free Radic Biol Med
January 2025
Department of Disaster Related Oral Health & Oxidative Stress/ESR Laboratories, Kanagawa Dental University, 82 Inaoka-cho, Yokosuka, Kanagawa 238-8580, Japan. Electronic address:
To evaluate oxidative stress involved in Down syndrome periodontal disease and pathological premature aging, reactive oxygen species (ROS) such as superoxide (O) and hydroxyl radical (HO) in human saliva were measured using electron spin resonance (ESR) spectroscopy. The groups consisted of 20 subjects in the Down syndrome (DS) child (DC) group (mean age 11.3 ± 4.
View Article and Find Full Text PDFCondylar Changes in Adult Patients with Unilateral Posterior Crossbite Following Microimplant-Assisted Rapid Palatal Expansion: A Retrospective CBCT Study.
J Stomatol Oral Maxillofac Surg
January 2025
Department of Orthodontics, Hubei-MOST KLOS & KLOBM, School & Hospital of Stomatology, Wuhan University, Wuhan, China.. Electronic address:
Objectives: This study aims to assess the alterations in condylar positioning in adult skeletal Class I patients with unilateral posterior crossbite after microimplant-assisted rapid palatal expansion (MARPE) treatment.
Methods: This retrospective study involving 30 participants (10 males, 20 females) average age 22.9 ± 4.
Visualizing the spatial distribution of Alprazolam in the mouse brain following nasal administration using desorption electrospray ionization mass spectrometry imaging.
Int J Pharm
January 2025
School of Pharmacy, Guilin Medical University, Guilin, Guangxi 541199, China. Electronic address:
Alprazolam (Alp), a triazolobenzodiazepine, is widely prescribed for the treatment of sleep disorders, anxiety, and panic disorder. While oral administration remains the standard route, its slow onset of action has prompted interest in intranasal delivery as an alternative, offers the potential for direct drug delivery to the brain. This study aims to develop a fast-acting intranasal formulation of Alp (Alp-nd).
View Article and Find Full Text PDFSovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.
Lancet Haematol
January 2025
National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China. Electronic address:
Background: Spleen tyrosine kinase inhibitors are potential treatment options for warm autoimmune haemolytic anaemia. This study aimed to assess the preliminary efficacy and safety of sovleplenib-an oral spleen tyrosine kinase inhibitor-in patients with warm autoimmune haemolytic anaemia in China. Here we report on the phase 2 results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!